摘要:
A mismatched double-stranded ribonucleic acid, which is an agonist for Toll-like receptor 3 (TLR3), is used in vitro or in vivo as an antimicrobial agent, antiproliferative agent, and/or immunostimulant. Poly(l:C11-14U) is a more selective agonist of TLR3 as compared to poly(l:C) even though the both double-stranded RNA are structurally analogous.
摘要:
A subset of human patients having chronic fatigue syndrome and impaired physical performance is treated using one or more different double-stranded ribonucleic acids (dsRNA) or other selective agonists of Toll-like receptor 3 (TLR3).
摘要:
Symptoms of viral infection are mitigated by administering to a subject exposed to a virus a protective or symptom-mitigating amount of a dsRNA and continuing administration until the subject's symptoms have improved.
摘要:
Vaccine protection against acute or chronic viral infection is facilitated by using as an adjuvant or immuno-stimulant, a dsRNA together with an anti-influenza vaccine.
摘要:
Vaccine protection against acute or chronic viral infection is facilitated by using as an adjuvant or immuno-stimulant, a dsRNA together with an anti-influenza vaccine.
摘要:
The invention relates to our discovery of a novel double-stranded ribonucleic acid (dsRNA) having specific biological activities, which includes acting as a selective agonist for activation of the Toll-like receptor 3. Its “rugged” molecular structure as measured by physico-chemical techniques is resistant to molecular unfolding (i.e., denaturation). This structure appears to be responsible for increased efficacy of dsRNA in therapeutic applications and improved biological activity (e.g., used as an immunoregulatory agent). Medicaments, processes for their manufacture, and methods for their use are provided herein.
摘要:
An antiviral/immunomodulatory response in an animal is induced by oral administration to an infected animal, including humans, of a human α-interferon. Methods of conferring resistance or mitigating the effects of exposure to a virus including avian influenza are described.
摘要:
A mixture of α-interferons (IFN-α) is used in vitro or in vivo as an antimicrobial agent or anticancer agent. It may be administered by topical application to oral or nasal, and/or buccal mucosa to combat the effects of infection by bacteria or protozoa, cancer, or other pathogenic disease process (e.g., autoimmune or neurodegenerative disease).